Mangoceuticals, Inc. Common Stock Cash Flow-to-Debt Ratio
Mangoceuticals, Inc. Common Stock cash flow-to-debt ratio. Mangoceuticals, Inc. Common Stock (MGRX) has a Cash Flow-to-Debt Ratio of -0.16x as of June 2026, meaning its operating cash flow of $-260.51K could theoretically repay 0% of its total liabilities ($1.65 Million) in one year. See how financially flexible is Mangoceuticals, Inc. Common Stock to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Mangoceuticals, Inc. Common Stock (2021–2025)
Cash flow-to-debt ratio of Mangoceuticals, Inc. Common Stock from 2021 to 2025. Historical debt coverage capacity for Mangoceuticals, Inc. Common Stock across 5 annual periods. Also explore net asset momentum of Mangoceuticals, Inc. Common Stock to track the company's year-over-year net asset growth rate.
Mangoceuticals, Inc. Common Stock Cash Flow-to-Debt Ratio by Year (2021–2025)
Mangoceuticals, Inc. Common Stock cash flow-to-debt ratio by year from 2021 to 2025. Year-by-year debt coverage analysis for Mangoceuticals, Inc. Common Stock. For the full cash flow conversion analysis, see Mangoceuticals, Inc. Common Stock (MGRX) cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -6.57x | $-5.85 Million | $890.57K | ▼ -92.5% |
| 2024 | -3.41x | $-4.86 Million | $1.43 Million | ▲ +86.5% |
| 2023 | -25.35x | $-7.00 Million | $276.04K | ▼ -632.8% |
| 2022 | -3.46x | $-1.35 Million | $389.26K | ▼ -675.4% |
| 2021 | -0.45x | $-17.52K | $39.27K | — |